Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CES2 | O00748 | 6/20 | 0.68 |
| ▸ | CES1 | P23141 | 6/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11523338 | 1.00 | MEN1 (0.81) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL11523332 | 1.00 | MEN1 (0.81) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL420190 | 0.92 | MEN1 (0.77) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL420709 | 0.91 | MEN1 (0.79) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL9346773 | 0.91 | MEN1 (0.81) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL9346767 | 0.91 | MEN1 (0.81) | MEN1KMT2ACES2CES1PTPN1 | |
| Beta-Amyrin Acetate SCHEMBL4938185 | 0.90 | MEN1 (1.00) | MEN1KMT2APTPN1USP2ALOX5 | |
| Beta-Amyrin Acetate SCHEMBL29437228 | 0.90 | MEN1 (1.00) | MEN1KMT2APTPN1USP2ALOX5 | |
| Beta-Amyrin Acetate SCHEMBL4938189 | 0.90 | MEN1 (1.00) | MEN1KMT2APTPN1USP2ALOX5 | |
| Beta-Amyrin Acetate SCHEMBL29602022 | 0.90 | MEN1 (1.00) | MEN1KMT2APTPN1USP2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892910-B1 | GLYCYRRHETINIC ACID DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY | ABBVIE INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140073700-A1 | GLYCYRRHETINIC ACID DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073700-A1 | GLYCYRRHETINIC ACID DERIVATIVES AND METHODS OF USE THEREOF | MPO, GSR, AGER | MEN1 4265/4885KMT2A 4447/4885CES2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.